Ronald Peck

Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine

Edith A. Perez, Guillermo Lerzo, Xavier Pivot et al. · Journal of Clinical Oncology · 2007 · 393 citations · Full text

Medicine, Oncology, Pharmacology +15

Effect of a Patient and Clinician Communication-Priming Intervention on Patient-Reported Goals-of-Care Discussions Between Patients With Serious Illness and Clinicians

J. Randall Curtis, Lois Downey, Anthony L. Back et al. · JAMA Internal Medicine · 2018 · 260 citations · Full text

Nursing, Communication, Communication In Serious Illness +16

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

Henri Roché, Louise Yelle, Francesco Cognetti et al. · Journal of Clinical Oncology · 2007 · 225 citations

Medicine, Oncology, Pharmacology +16

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Joseph A. Sparano, Eduard Vrdoljak, O. Rixe et al. · Journal of Clinical Oncology · 2010 · 219 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Johan Vansteenkiste, Primo N. Lara, Thierry Le Chevalier et al. · Journal of Clinical Oncology · 2007 · 129 citations

Medicine, Oncology, Pharmacology +13